Northwire Canada EditionSaturday, October 17, 2026
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
M&A / Property

Rocket Doctor completes acquisition of Alea Health

AIDR · Price

Executive Summary

  • Rocket Doctor AI Inc. has closed its previously announced acquisition of Alea Health Holdings Ltd. pursuant to a definitive share purchase agreement.
  • The transaction consideration comprises a $15,000 USD cash payment and the issuance of 285,712 common shares to Alea shareholders, alongside the assumption of a $180,000 USD SAFE note.
  • Alea’s technology and team will be integrated into Rocket Doctor AI’s platform to enhance clinical decision support, streamline workflows, and expand its AI-powered digital health ecosystem across North America.

Key Details

  • Transaction Structure: Acquisition of 100% of issued and outstanding ordinary shares of Alea Health Holdings Ltd.
  • Consideration:
  • Cash payment of $15,000 USD (previously paid as an acquisition deposit)
  • Issuance of 285,712 common shares pro rata to Alea shareholders, with a deemed value of $0.70 per share
  • Assumed Liabilities: Assumed and agreed to satisfy Alea’s Simple Agreement for Future Equity (SAFE) note, carrying a $180,000 USD principal balance, payable in equal monthly installments of $22,500 USD until paid in full (first installment paid concurrently with closing)
  • Securities & Restrictions: All securities issued under prospectus exemptions per National Instrument 45-106; subject to a statutory hold period of four months and one day; consideration shares subject to a 28-month contractual escrow release schedule (20% released every four months, beginning on the first anniversary of closing)
  • Integration & Strategy: Alea’s technology and team will be integrated into Rocket Doctor AI’s platform and product roadmap to enhance clinical workflows, data-driven decision support, and care consistency across its physician-led marketplace
  • Transaction Terms: Arm’s-length transaction with no finders’ fees paid; no long-term liabilities assumed other than the specified SAFE note

Notable Quotes

  • Dr. Essam Hamza, CEO of Rocket Doctor AI: "This acquisition represents an important step forward in executing our strategy to build a scalable, physician-led digital health ecosystem... Together, we are better positioned to support clinicians, improve care consistency and expand access to high-quality health care for patients across North America, including underserved and remote communities."
  • Richard Dallala, Founder & CEO of Alea Health: "Joining Rocket Doctor AI allows Alea's technology to scale within a broader clinical and operational framework that is deeply aligned with our original mission... We're excited to see our work integrated into a platform that prioritizes physician leadership, evidence-based care and meaningful improvements in patient outcomes."
Read the original news release →

More from Rocket Doctor AI Inc